Vigil Neuroscience (NASDAQ:VIGL) Price Target Cut to $14.00 by Analysts at HC Wainwright

Vigil Neuroscience (NASDAQ:VIGL - Free Report) had its price target decreased by HC Wainwright from $17.00 to $14.00 in a research note released on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other equities analysts have also commented on the company. JMP Securities reiterated a "market outperform" rating and issued a $22.00 target price on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Guggenheim reissued a "buy" rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. Finally, William Blair initiated coverage on Vigil Neuroscience in a research report on Wednesday, December 4th. They set an "outperform" rating for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $16.25.

Vigil Neuroscience Stock Performance

Vigil Neuroscience stock traded down $0.01 during trading on Friday, hitting $1.97. The company's stock had a trading volume of 284,357 shares, compared to its average volume of 468,780. The stock has a market capitalization of $80.53 million, a price-to-earnings ratio of -0.96 and a beta of 1.82. The stock's fifty day moving average is $2.34 and its 200 day moving average is $2.77. Vigil Neuroscience has a 1-year low of $1.49 and a 1-year high of $6.06.

Remove Ads

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last released its earnings results on Thursday, March 13th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.08). On average, research analysts anticipate that Vigil Neuroscience will post -2.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Vigil Neuroscience

Institutional investors and hedge funds have recently modified their holdings of the stock. abrdn plc boosted its position in shares of Vigil Neuroscience by 124.9% in the fourth quarter. abrdn plc now owns 528,472 shares of the company's stock worth $898,000 after buying an additional 293,461 shares during the period. Geode Capital Management LLC boosted its position in shares of Vigil Neuroscience by 41.9% in the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company's stock worth $769,000 after buying an additional 66,712 shares during the period. Verition Fund Management LLC purchased a new stake in shares of Vigil Neuroscience in the third quarter worth about $442,000. Walleye Capital LLC boosted its position in shares of Vigil Neuroscience by 334.4% in the third quarter. Walleye Capital LLC now owns 119,792 shares of the company's stock worth $407,000 after buying an additional 92,217 shares during the period. Finally, Point72 Asset Management L.P. boosted its position in shares of Vigil Neuroscience by 7.7% in the third quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company's stock worth $5,440,000 after buying an additional 115,000 shares during the period. Hedge funds and other institutional investors own 83.64% of the company's stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.